Adam

Effective nature finance needs better data, analysis and tools

Alarming degradation of biodiversity has prompted initiatives for financial investments in nature both globally and in Europe. Besides strengthening biodiversity, such investments can have other important benefits, such as supporting climate action, food security, and improving quality of life in cities. European Environment Agency’s (EEA) new briefing highlights that better data, impact analysis and coordination […]

Zero pollution: 2030 targets within reach but need stronger action

The European Commission is publishing its first Zero Pollution Monitoring and Outlook report setting pathways to cleaner air, water and soil. The Commission report, together with the European Environment Agency’s monitoring assessment, shows that EU policies have contributed to reducing air pollution as well as pollution from pesticides. However, in other areas such as harmful […]

The General Board of the European Systemic Risk Board held its 48th regular meeting on 1 December 2022

At its meeting on 1 December 2022, the General Board of the European Systemic Risk Board (ESRB) noted that risks to financial stability have increased over the past few months. This reflects persistently high inflation, a tightening of financial conditions and a perceptible deterioration in the economic outlook. While third-quarter GDP growth in the European Union […]

ECB Consumer Expectations Survey Results – October 2022

Compared with September: consumer expectations for inflation 12 months ahead increased further, while expectations for inflation three years ahead remained unchanged; inflation expectations remained well below the perceived past inflation rate, particularly at the medium-term horizon of three years; expectations for both nominal spending and income growth over the next 12 months increased, and expected […]

ETF concludes that bivalent original/Omicron BA.4-5 mRNA vaccines may be used for primary vaccination

EMA’s Emergency Task Force (ETF) considers that adapted mRNA bivalent vaccines targeting the original strain and Omicron BA.4-5 subvariants of SARS-CoV-2 may be used for primary (initial) vaccination. These vaccines are currently only authorised as boosters.